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ABSTRACT 
Background. Although both the 13-valent pneumococcal conjugate vaccine (PCV13) and the 
10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine 
(PHiD-CV) are widely used, it is unclear how interchangeable they are in terms of 
immunogenicity. 
Methods. Two phase 3, open-label, multicenter studies were conducted to assess the 
immunogenicity and safety of a booster dose of PCV13 in children primed with PHiD-CV or 
PCV13. In the Czech Republic, 12–15-month-old children received a PCV13 booster after 3-
dose priming with either PHiD-CV or PCV13. In Slovakia, 11–12-month-old children 
received PCV13 following 2-dose priming with either PHiD-CV or PCV13. Serum IgG 
concentrations were assessed by enzyme-linked immunosorbent assay and functional 
antibodies were assessed by opsonophagocytic assay (OPA) before and 1 and 12 months after 
the booster dose. The primary objective of these studies was to assess non-inferiority of OPA 
titers for serotype 19A in PHiD-CV-primed subjects compared to those in PCV13-primed 
children 1 month post-booster. 
Results. A total of 98 subjects in the Czech Republic and 89 subjects in Slovakia were 
included. One month after the PCV13 booster dose, the IgG and OPA immune responses to 
serotype 19A in subjects primed with 2 or 3doses of PHiD-CV were not inferior to those in 
subjects primed with PCV13. Non-inferior and persistent immune responses to most other 
vaccine serotypes were also observed after the PCV13 booster in PHiD-CV-primed subjects. 
No safety issues were raised in either study. 
Conclusions. Overall, robust IgG and OPA immunological responses were observed after 
booster vaccination with PCV13 in children primed with 2 or 3 doses of PHiD-CV or PCV13, 
including for serotypes not included in PHiD-CV. These results suggest that both vaccines are 
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interchangeable in terms of safety and immunogenicity and that PCV13 can be used as a 
booster in the context of mixed schedules. (EudraCT numbers: 2012-005366-35 and 2012-
005367-27) 
 
Keywords: pneumococcal conjugate vaccine, interchangeability, immunisation schedule, 
immunogenicity, serotype 19A 
 
1. INTRODUCTION1 
Since the introduction of the first pneumococcal conjugate vaccine (PCV) in 2000, invasive 
and non-invasive diseases caused by Streptococcus pneumoniae have dramatically decreased 
worldwide [1, 2]. This 7-valent vaccine (PCV7; Pfizer Inc.) included the capsular 
polysaccharides of the seven most frequent pneumococcal serotypes in the United States at 
the time of licensure (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) [3]. However, a small but 
significant rise in infections caused by non-PCV7 serotypes, notably serotype 19A, has 
occurred in several countries, thereby eroding the benefits of vaccination [4-6]. The burden of 
disease caused by serotype 19A is of particular concern because it is highly invasive and 
frequently multiresistant to antibiotics [7]. To limit the rise of infections by non-vaccine 
serotypes and increase overall serotype coverage, second-generation PCVs with extended 
valencies became available in 2009 and have gradually replaced PCV7. The 10-valent 
                                                 
1 Abbreviations: AE, adverse event; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; GMC, geometric 
mean concentration; GMT, geometric mean titer; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent 
pneumococcal conjugate vaccine; PHiD-CV, pneumococcal non-typeable Haemophilus influenzae protein D-conjugate 
vaccine; SAE, serious AE. 
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pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV; 
GSK Vaccines) includes the PCV7 serotypes plus serotypes 1, 5, and 7F, whereas the 13-
valent PCV (PCV13; Pfizer Inc.) includes the PHiD-CV serotypes plus serotypes 3, 6A, and 
19A. Both PHiD-CV and PCV13 have been licensed for protection against invasive 
pneumococcal disease on the basis of immunological non-inferiority compared to the licensed 
PCV7 [8].  
Both vaccines were originally licensed in a 4-dose schedule consisting of 3 primary doses, 
plus a booster dose administered at least 6 months after the third dose (3+1 schedule) [9]. The 
first dose can be administered from 6 weeks of age and the booster dose should be 
administered between 11 and 15 months of age. Several alternative schedules are also used. 
One consists of 2 primary doses given 2 months apart, followed by a booster dose at least 6 
months after the second dose (2+1 schedule) [9]. This schedule was first evaluated and 
implemented in the United Kingdom [10] and subsequently in several other countries [6]. In 
developing countries, a 3-dose primary schedule without a booster dose (3+0 schedule) is 
often used to match the schedules of the Expanded Programme on Immunisation [11]. 
Although immunogenicity of both PHiD-CV and PCV13 has been compared to that of PCV7 
[12, 13], only a few studies have directly compared PHiD-CV and PCV13 [14-16]. In this 
study, we directly compared the immunogenicity and safety of PCV13 when administered as 
a booster dose in children primed with PHiD-CV or PCV13, either as a 2- or 3-dose schedule. 
2. MATERIALS AND METHODS 
2.1. Study design and subjects 
These were two phase 3, multicenter, open-label studies conducted in 10 centers in the Czech 
Republic (EudraCT, 2012-005366-35) and in 8 centers in Slovakia (EudraCT, 2012-005367-
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27) to assess immunogenicity and safety of alternative vaccination schedules with 
pneumococcal conjugate vaccines. Both study protocols were approved by the relevant 
independent ethics committees and the studies were conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was 
obtained from parents or legal representatives of all children before enrolment. 
In the Czech Republic (3+1 schedule), healthy children were eligible if they were 12–15 
months of age and had completed a 3-dose vaccination course before 7 months of age with 
either the 10-valent PCV (PHiD-CV; Synflorix™, GSK Vaccines, Rixensart, Belgium) or the 
13-valent PCV (PCV13; Prevenar/Prevnar 13™, Pfizer, New York, NY). In Slovakia (2+1 
schedule), healthy children were eligible if they were 11–12 months of age and had completed 
a 2-dose vaccination course before 6 months of age with either PHiD-CV or PCV13.  
Children were excluded if they had received a previous booster dose against S. pneumoniae, 
any investigational product within 30 days preceding the study vaccination, immunoglobulins 
or any blood product within 3 months preceding the study vaccination (or were to receive 
these during the study period), a vaccine (except licensed influenza or diphtheria-tetanus-
acellular pertussis vaccines) within 30 days before or after the study vaccination, 
immunosuppressants or other immune-modifying drugs for >14 days since birth; had any 
confirmed or suspected immunodeficient condition or family history of immunodeficiency, 
serious chronic disease, history of neurological disorders or seizures; had any 
contraindications to vaccination such as allergies; had acute infection or fever at enrollment. 
2.2. Study vaccines 
All children received one booster dose of PCV13 by intramuscular injection (0.5 mL) in the 
anterolateral region of the thigh or the deltoid region. This vaccine contains capsular 
polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, all 
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conjugated to the diphtheria CRM197 carrier protein. Co-administration of the routine 
diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-H. influenzae type b 
vaccine (DTaP-HBV-IPV/Hib; Infanrix hexa™; GSK Vaccines) was allowed in the Czech 
Republic and was mandatory in Slovakia. 
2.3. Assessment of immunogenicity 
Blood samples were taken for immunogenicity analyses before the booster dose (study month 
0) and 1 and 12 months after the booster dose. Sera were stored at –20°C until analysis. 
Analyses were performed at the World Health Organization pneumococcal reference 
laboratory (University College London, United Kingdom). Immunoglobulin G (IgG) serum 
concentrations specific for the 13 vaccine serotypes were measured using an enzyme-linked 
immunosorbent assay (ELISA) after adsorption with cell-wall and 22F polysaccharides to 
increase the assay specificity [17]. A standardized opsonophagocytic assay (OPA) was used to 
measure functional antibodies against the same serotypes [18]. The OPA response to vaccine-
related serotype 6C [19] was also measured, although not planned in the protocol. The OPA 
titer was defined as the reciprocal of the lowest serum dilution that induces ≥50% bacterial 
cell death compared to the assay control. 
2.4. Assessment of safety and reactogenicity 
Solicited local reactions (pain, redness, and swelling at the injection site) and solicited 
systemic reactions (drowsiness, fever, irritability/fussiness, and loss of appetite) were 
recorded by parents on diary cards for 4 days after vaccination (days 0–3). Unsolicited 
adverse events (AEs) were recorded for 31 days (days 0–30) after vaccination and serious 
adverse events (SAEs) were recorded over the entire study period. The intensity of solicited 
reactions and AEs was scored on a scale from 1 (mild) to 3 (severe). Redness and swelling at 
the injection site were scored as 1 for >0 to ≤20 mm diameter, 2 for >20 to ≤30 mm, and 3 for 
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>30 mm. Fever was defined as rectal temperature ≥38.0°C or oral, axillary, or tympanic 
temperature ≥37.5°C. Grade 3 fever was defined as rectal temperature >40C or axillary, oral, 
or tympanic temperature >39.5C. Pain was scored as 1 for minor reaction to touch, 2 for 
crying on touch, and 3 for crying when limb is moved or spontaneously painful. The other 
solicited reactions were scored as 1 if they did not affect normal activity, 2 if they interfered 
with normal activity, and 3 if they prevented normal daily activity. All solicited local 
reactions were considered vaccination-related. Causality of solicited systemic reactions, 
unsolicited AEs, and SAEs was determined by the investigators.  
2.5. Statistical analysis 
Safety was analyzed in the full analysis set, which included all subjects who received a 
booster dose of PCV13. Immunogenicity was analyzed in the per protocol set, which included 
all subjects who received the booster dose of PCV13 according to protocol and who had at 
least one valid IgG or OPA result. 
At each visit and for each serotype, antibody geometric mean concentrations (GMCs) and 
OPA geometric mean titers (GMTs) were determined with 2-sided 95% confidence intervals 
(CI). The percentages of participants reaching the predefined immunological thresholds (OPA 
titer ≥8 and IgG concentration ≥0.35 μg/mL) were also calculated [20, 21]. No formal 
statistical tests were performed for safety data. 
The primary objective of the studies was to assess non-inferiority of the OPA GMT to 
serotype 19A in subjects primed with PHiD-CV compared to those primed with PCV13, 1 
month after the PCV13 booster dose administered at 12–15 months in the Czech Republic 
(3+1) and at 11–12 months in Slovakia (2+1). The secondary confirmatory objective was to 
assess non-inferiority of the IgG response to serotype 19A 1 month post-booster. Non-
inferiority was demonstrated if the lower limit of the 2-sided 95% CI for the OPA GMT ratio 
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or the IgG GMC ratio (PHiD-CV group over PCV13 group) was >0.5. Other secondary 
exploratory objectives included IgG and OPA responses against the other serotypes at month 
1 and against all serotypes at month 12, and assessment of safety and reactogenicity of the 
PCV13 booster dose.  
In both studies, a sample size of 92 subjects (46 participants in both vaccine groups) was 
calculated to provide 90% power for assessing non-inferiority in pneumococcal serotype 19A 
antibody response rate with a limit of 10% at a 2-sided 5% significance level, assuming a 98% 
response rate in the PHiD-CV group and a 10% drop-out rate. All significance tests were two-
tailed. A P-value ≤0.05 was considered to indicate statistical significance. Statistical analyses 
were performed with SAS™ version 9.1 or higher (SAS Institute, Cary, NC). 
3. RESULTS 
3.1. Subjects 
The study in the Czech Republic was conducted between March 12, 2013 and October 7, 
2014 and the study in Slovakia between March 5, 2013 and November 14, 2014. Overall, 98 
children were enrolled in the Czech Republic and 89 in Slovakia (Figure 1). All subjects in 
both studies received the PCV13 booster dose and were included in the full analysis set. 
Twelve months post-booster, 94.1%–98.0% of subjects per group were included in the per 
protocol set. In the Czech Republic, DTaP-HBV-IPV/Hib was co-administered in 44 subjects 
(83.0%) in the PHiD-CV-primed group and 39 (86.7%) in the PCV13-primed group. In 
Slovakia, one subject in the PCV13 group did not receive DTaP-HBV-IPV/Hib concomitantly 
with PCV13, although requested by the protocol. 
In both studies, most participants were male and Caucasian (Table 1). In the Czech Republic, 
73.3% of the subjects in the PCV13 group were male compared to 56.6% in the PHiD-CV 
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group. Per study design, participants were older in the Czech Republic (mean age, 12.6 
months) than in Slovakia (mean age, 11.3 months). 
3.2. Immune responses against serotype 19A 
Before the booster dose, OPA titers against serotype 19A were higher in children primed with 
PCV13 than those primed with PHiD-CV in both studies (Supplementary Table 1). One 
month post-booster, OPA GMTs increased markedly with both schedules and, subsequently, 
decreased between months 1 and 12. In both studies, post-booster 19A OPA titers were 
comparable in PHiD-CV and PCV13 groups. At month 1, all subjects had 19A OPA GMTs 
≥8 in both groups in both studies, whereas at 12 months, fewer subjects had GMTs ≥8 in the 
PHiD-CV groups (84.3%–86.8%) than in the PCV13 groups (93.9%–97.8%) (Supplementary 
Table 2). 
One month post-booster, the OPA GMT ratio (PHiD-CV group over PCV13 group) for 
serotype 19A was 1.24 (95% CI, 0.84–1.82) with the 3+1 schedule and 0.81 (95% CI, 0.54–
1.20) with the 2+1 schedule (Figure 2). Because the lower limit values of the 95% CI were 
higher than the 0.5 arbitrary margin in both studies, the OPA titers in PHiD-CV-primed 
children were not inferior to those in PCV13-primed children. Thus, the primary confirmatory 
objective was met in both studies. However, 12 months post-booster, 19A OPA titers in 
PHID-CV-primed children were inferior to those in PCV13-primed children in both studies. 
One month post-booster, 19A IgG GMCs were similar between the two schedules 
(Supplementary Table 3). Compared to pre-booster concentrations, they increased 15–29 fold 
with the 3+1 schedule and 12–24 fold with the 2+1 schedule, and decreased between months 
1 and 12. All subjects had GMCs ≥0.35 mg/mL at month 1, and between 82.4% and 98.0%. at 
months 12 (Supplementary Table 4). In both studies, the percentages were comparable 
between groups. The mean IgG GMC ratio for serotype 19A 1 month post-booster was 1.36 
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(95% CI, 0.90–2.08) with the 3+1 schedule and 1.25 (95% CI, 0.83–1.87) with the 2+1 
schedule (Figure 2). Therefore, in both studies, the antibody concentrations in PHiD-CV-
primed children were not inferior to those in PCV13-primed children. Non-inferiority was 
also shown at 12 months.  
3.3. OPA responses to the other vaccine serotypes 
One month post-booster, the OPA titers increased substantially for all the other serotypes in 
both studies (Supplementary Table 1). With both schedules, OPA GMTs were similar 
between groups for serotypes 1, 3, 5, 6B, 18C, 19F, and 23F but, with the 3+1 schedule, they 
were higher in the PCV13 group for serotypes 4, 6A, 6C, 7F, 9V, and 14. In both studies, all 
subjects had OPA titers ≥8 in the two groups for all serotypes, except for serotypes 3 and 6A 
in the PHiD-CV groups (≥97.4%) (Supplementary Table 2). For the vaccine-related serotype 
6C, the proportions were slightly lower in the 2+1 than in the 3+1 schedule (92.1%–93.9% vs. 
98%–100%).  
With the 3+1 schedule, OPA GMTs in PHiD-CV-primed subjects were not inferior to those in 
PCV13-primed subjects for six serotypes (1, 3, 5, 6B, 18C, and 19F) and were inferior for 
seven (4, 6A, 6C, 7F, 9V, 14, 23F) (Figure 2). With the 2+1 schedule, OPA GMTs were not 
inferior in PHiD-CV-primed subjects for seven serotypes (1, 3, 5, 6A, 6B, 9V, and 19F) and 
inferior for six (4, 6C, 7F, 14, 18C, and 23F).  
3.4. Anti-pneumococcal IgG responses to the other serotypes 
IgG GMCs increased for all serotypes 1 month post-booster in both studies (Supplementary 
Table 3). GMCs were comparable between groups for all vaccine serotypes, except for 
serotypes 6B and 19F, which were higher in the PHiD-CV group than in the PCV13 group in 
both studies. All subjects had antibody concentrations ≥0.35 mg/mL for serotypes 1, 4, 7F, 
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14, 18C, and 19F in the two groups in both studies (Supplementary Table 4). For serotypes 3, 
5, 6A, 6B, 9V, and 23F, the percentages ranged between 84.2% and 100.0%. When PHiD-CV 
or PCV13 were administered as 3+1 or 2+1 schedules, non-inferiority of the IgG GMCs after 
PHiD-CV priming was shown for all the other serotypes, except for serotype 14 in the 2+1 
schedule (Figure 3).  
3.5. Persistence of the OPA and IgG responses to the other vaccine serotypes 
Twelve months after the booster dose, the OPA GMTs and the IgG GMCs decreased 
approximately to baseline levels for all the other serotypes after both 3+1 and 2+1 schedules 
(Supplementary Tables 1 and 3). Although the proportions of subjects with OPA titers ≥8 also 
decreased over time, they remained >90% for serotypes 6B, 7F, and 23F and between 47.4% 
and 100% for serotypes 4, 5, 6A, 6C, 9V, and 19F (Supplementary Table 2). The lowest 
proportions were for serotypes 1 and 3 (13%−61%). Overall, no major differences were seen 
between groups, except for serotype 1 in the 3+1 schedule (43.1% in the PHiD-CV group vs. 
13.3% in the PCV13 group) and serotype 4 in the 2+1 schedule (47.4% in the PHiD-CV 
group vs. 81.6% in the PCV13 group). The proportions of subjects with IgG concentrations 
above the protective threshold of 0.35 µg/mL also decreased over time and were ≥76.5% for 
serotypes 6A, 6B, 7F, 14, and 19F and between 15.7% and 65.8% for serotypes 1, 3, 4, 5, 9V, 
18C, and 23F. In both studies, no major differences were seen between vaccine groups. 
Twelve months post-booster, the OPA GMTs in PHiD-CV-primed subjects were not inferior 
to those in PCV13-primed subjects for serotypes 1, 3, 5, 6B, 14, 18C, and 19F with the 3+1 
schedule and for serotypes 1, 3, 5, and 6A with the 2+1 schedule (Figure 2). The IgG 
concentrations after PHiD-CV priming were not inferior for all serotypes with the 3+1 
schedule and for all serotypes except serotypes 4 and 23F with the 2+1 schedule (Figure 3). 
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3.6.  Safety and reactogenicity of the PCV13 booster dose 
Overall, solicited local and systemic reactions were reported in 82.7% of subjects in the 3+1 
schedule and 86.5% in the 2+1 schedule (Table 2). In the 3+1 schedule, one subject had a 
grade 3 local reaction (pain) and two subjects had grade 3 systemic reactions 
(irritability/fussiness in both). In the 2+1 schedule, three subjects had grade 3 pain at the 
injection site. One subject had one grade 3 systemic reaction (irritability/fussiness) and one 
subject had two (irritability/fussiness and loss of appetite). 
Overall, approximately 40% of subjects in both studies had unsolicited AEs within 1 month 
after the PCV13 booster dose (Table 2). These AEs were mainly respiratory conditions and of 
mild intensity. In the 3+1 schedule, the frequency of subjects reporting AEs and the number 
of AEs were approximately two fold lower in the PHiD-CV group than in the PCV13 group. 
Two AEs, erythema and rhinitis, were considered vaccine-related by the investigators, both in 
the PCV13 group. They began within 3 days of the booster dose, were of mild intensity, and 
resolved without sequelae. In the 2+1 schedule, one subject in the PHiD-CV group had two 
AEs (acute gastroenteritis and dehydration) and one subject in the PCV13 group had one AE 
(sideropenic anemia) considered vaccine-related.  
Four subjects in the 3+1 schedule had SAEs (acute laryngitis, head and neck burn, herniotomy 
in the PCV13 group; falling on head in the PHiD-CV group) and three in the 2+1 schedule 
(severe dyspepsia in the PCV13 group; respiratory tract inflammation [rhinopharyngitis, 
obstructive bronchitis, and unilateral pneumonia] and acute gastroenteritis with dehydration in 
the PHiD-CV group). None of the SAEs were considered related to the study vaccine. 
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4. DISCUSSION 
Our results show that a PCV13 booster dose, either in a 3+1 or a 2+1 schedule, is 
immunogenic and well tolerated in PCV13- or PHiD-CV-primed children. The primary and 
secondary confirmatory objectives were met for both studies. One month post-booster, the 
IgG and OPA immune responses to serotype 19A in PHiD-CV-primed children were not 
inferior to those in PCV13-primed children, as part of either 3+1 or 2+1 schedules.  
An IgG concentration of 0.35 µg/mL correlates with protection at a population level and is 
therefore used as a protective threshold for evaluating PCVs [8]However, because antibody 
production determined by ELISA does not necessarily reflect functional potential, in vitro 
OPA assays are considered the best surrogate to evaluate protection provided by PCVs [22, 
23]. Although non-inferiority was shown for more serotypes in terms of IgG than OPA 
responses, nearly all subjects primed with PHiD-CV or PCV13 had OPA titers above the 
chosen threshold at month 1. This suggests that functional antibodies are induced even for 
serotypes for which the immune response was considered inferior in PHiD-CV-primed 
children. The IgG GMCs and the OPA GMTs decreased over time but the proportions of 
subjects with immune responses above the thresholds remained high for most serotypes 12 
months post-booster. This suggests that, although the immune responses waned after the 
booster dose, this decline may be of limited clinical relevance for most serotypes. 
Although serotypes 3, 6A, and 19A are not included in PHiD-CV, high IgG GMCs and OPA 
GMTs against these serotypes were found after the PCV13 booster dose in PHiD-CV-primed 
subjects. Mixed PHiD-CV-PCV13 schedules may therefore offer a reasonable alternative in 
settings with high occurrence of 19A disease. Indeed, in Quebec, Canada, a mixed schedule 
consisting of 2 primary PHiD-CV doses followed by a PCV13 booster provided similar 
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protection against overall and vaccine-type invasive pneumococcal disease, including for 
serotype 19A, as compared to schedules using only PHiD-CV or PCV13 [24]. 
One previous study has evaluated the interchangeability of PHiD-CV and PCV13 when given 
as booster doses in mixed schedules [14]. The study showed that a PHiD-CV booster is 
generally less immunogenic than a PCV13 booster in PCV13-primed children. Our studies 
evaluated for the first time a booster dose with PCV13 in children primed with PHiD-CV or 
PCV13. Our results suggest that these two vaccines are interchangeable as boosters and 
induce strong immune responses against vaccine serotypes. Using mixed schedules would 
have several advantages over standard schedules. The nontypeable H. influenzae protein D is 
used as a carrier protein for 8 of the 10 serotypes included in PHiD-CV. Because this protein 
is not included in any other vaccine, the risk of immune interference is minimal [25].  
The reactogenicity and safety profiles of the PCV13 booster dose were comparable both 
schedules. In both studies, the frequency and severity of the solicited reactions and the 
unsolicited AEs in both study groups corresponded to those commonly observed after 
administration of vaccines. These results suggest that using a PCV13 booster after PHiD-CV 
priming does not raise any safety issues, as expected. Indeed, a switch from PHiD-CV to 
PCV13 has been introduced in the immunization programs in several countries, and no safety 
issues were raised during the transition period [26] (ref).  
Our studies have some limitations. The sample size of the studies, which was powered based 
on serotype 19A responses, may not be sufficient for testing non-inferiority of the other 
serotypes. Furthermore, multiplicity of comparisons was not taken into account, which could 
influence the results in any direction. The 3+1 and 2+1 schedules were assessed in two 
different studies conducted in different countries, which may also limit comparisons between 
the studies. However, the immunological analyses were performed by the same laboratory to 
limit the risk of bias. 
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In conclusion, our results suggest that a PCV13 booster in PHiD-CV primed children could be 
a promising vaccination strategy to improve clinical protection against three additional 
serotypes, although the clinical relevance of the observed differences in IgG and OPA 
responses between groups is currently unknown. When given as simplified 2+1 schedules, 
mixed schedules could also improve vaccine uptake and reduce the cost of the vaccination 
course. 
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TABLES 
Table 1. Baseline demographic characteristics of participants 
Characteristics, n (%) 
3+1 schedule (Czech Republic)  2+1 schedule (Slovakia) 
PHiD-CV 
group 
N = 53 
PCV13 
group 
N = 45 
Total 
N = 98 
 PHiD-CV 
group 
N = 39 
PCV13 
group 
N = 50 
Total 
N = 89 
Age (months)     
 Mean (SD) 12.9 (1.1) 12.3 (0.6) 12.6 (1.0)  11.3 (0.6)  11.4 (0.5) 11.3 (0.5) 
 Range 12.0–16.0 12.0–14.0 12.0–16.0  10.0–13.0  11.0–13.0 10.0–13.0 
Sex     
 Female 23 (43.4%) 12 (26.7%) 35 (35.7%)  16 (41.0%)  21 (42.0%) 37 (41.6%) 
 Male 30 (56.6%) 33 (73.3%) 63 (64.3%)  23 (59.0%)  29 (58.0%) 52 (58.4%) 
Race     
 Caucasian 53 (100.0%) 45 (100.0%) 98 (100.0%)  39 (100.0%)  49 (98.0%) 88 (98.9%) 
 Other 0  0  0   0  1 (2.0%) 1 (1.1%) 
PCV13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-
typeable Haemophilus influenzae protein D conjugate vaccine; SD, standard deviation. 
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Table 2. Safety and reactogenicity by subject 
 3+1 schedule (Czech Republic)  2+1 schedule (Slovakia) 
 
PHiD-CV 
(N = 53) 
PCV13 
(N = 45) 
Total 
(N = 98) 
 PHiD-CV 
(N = 39) 
PCV13 
(N = 50) 
Total 
(N = 89) 
Symptom 
n subjects 
(%) 
n AEs n subjects (%) n AEs 
n subjects 
(%) 
n AEs 
 n subjects 
(%) 
n AEs 
n subjects 
(%) 
n AEs 
n subjects 
(%) 
n AEs 
Reactogenicity      
Local reactions 
 Any 45 (84.9%) - 36 (80.0%) - 81 (82.7%) -  32 (82.1%) - 45 (90.0%) - 77 (86.5%) - 
 Grade 3 1 (1.9%) 1 0 0 1 (1.0%) 1  2 (5.1%) 2 1 (2.0%) 1 3 (3.4%) 3 
Systemic reactions 
 Any 44 (83.0%) - 37 (82.2%) - 81 (82.7%) -  29 (74.4%) - 45 (90.0%) - 74 (83.1%) - 
 Grade 3 0 0 2 (4.4%) 2 2 (2.0%) 2  1 (2.6%) 2 1 (2.0%) 1 2 (2.2%) 3 
Safety      
Adverse events 
 Any 14 (26.4%) 23 26 (57.8%) 60 40 (40.8%) 83  15 (38.5%) 32 21 (42.0%) 31 36 (40.4%) 63 
 Severe 1 (1.9%) 1 3 (6.7%) 4 4 (4.1%) 5  0 0 1 (2.0%) 1 1 (1.1%) 1 
 Vaccination
-related 
0 0 2 (4.4%) 2 2 (2.0%) 2  1 (2.6%) 2 1 (2.0%) 1 2 (2.2%) 3 
Serious adverse events 
 Any 1 (1.9%) 1 3 (6.7%) 3 4 (4.1%) 4  2 (5.1%) 4 1 (2.0%) 1 3 (3.4%) 5 
AEs, adverse events; PCV13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus 
influenzae protein D conjugate vaccine 
PCV mixed schedules  Draft 2 
Target journal: Vaccine CONFIDENTIAL 10 Feb 2017 
25 
LEGENDS TO FIGURES 
Figure 1. Flowchart of participants 
FAS, full analysis set; DTaP-HBV-IPV/Hib, diphtheria-tetanus-acellular pertussis-hepatitis B-
inactivated polio-Haemophilus influenzae type b vaccine; PCV13, 13-valent pneumococcal 
conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae 
protein D conjugate vaccine; PPS, per protocol set. 
 
Figure 2. PHiD-CV/PCV13 ratio of anti-pneumococcal OPA titers 1 and 12 months after the 
PCV13 booster dose 
Ratios of OPA geometric mean titer in PHID-CV over PCV13 recipients at 1 month and 12 
months after the booster dose. The error bars indicate 95% confidence intervals and the red 
dotted line the arbitrary margin for non-inferiority.  
 
Figure 3. PHiD-CV/PCV13 ratio of anti-pneumococcal IgG concentrations 1 and 12 months 
after the PCV13 booster dose 
Ratios of IgG geometric mean concentration in PHID-CV over PCV13 recipients at 1 month 
and 12 months after the booster dose. The error bars indicate 95% confidence intervals and 
the red dotted line the arbitrary margin for non-inferiority.  
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Figure 1.  
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Figure 2.  
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Supplementary Table 1. OPA geometric mean titers before and after the PCV13 booster 
dose 
Serotype 
3+1 schedule (Czech Republic)  2+1 schedule (Slovakia) 
PHiD-CV group 
N = 53 
PCV13 group 
N = 45 
 PHiD-CV group 
N = 39 
PCV13 group 
N = 49 
 N GMT (95% CI) N GMT (95% CI)  N GMT (95% CI) N GMT (95% CI) 
Serotype 1       
 Month 0 51 5.6 (4.5; 6.9) 44 5.7 (4.5; 7.1)  37 7.7 (5.4; 10.8) 49 6.8 (5.3; 8.8) 
 Month 1 51 287.7 
(213.7; 387.3) 
45  177.6 
(135.1; 233.4) 
 38 291.8 
(197.2; 431.8) 
49 226.8 
(161.7; 318.0) 
 Month 12 46 11.0 (7.6; 15.8) 44  5.7 (4.3; 7.7)  37 11.4 (7.6; 17.3) 48 11.6 (8.5; 15.7) 
Serotype 3       
 Month 0 50 4.9 (3.8; 6.2) 44 7.5 (5.2; 10.8)  38 4.4 (3.9. 4.9) 46 11.7 (8.1. 16.8) 
 Month 1 51 205.5 
(164.5; 256.6) 
45 128.0 
(92.3; 177.6) 
 38 135.1 
(93.5; 195.0) 
49 135.4 
(105.3; 174.2) 
 Month 12 40 12.5 (8.6; 18.3) 43 7.9 (5.6; 11.1)  32 14.3 (9.1; 22.5) 40 16.3 (10.6; 25.1) 
Serotype 4       
 Month 0 49 72.3 (46.1; 113.3) 43 60.0 (33.0; 109.1)  35 43.8 (23.1; 82.9) 47   43.2 (27.2; 68.5) 
 Month 1 51 1691.3 
(1366.1; 2093.9) 
45 3455.1 
(2672.6; 4466.7) 
 38 1372.1 
(1067.6; 1763.4) 
49 1995.2 
(1598.0; 2491.2) 
 Month 12 46 44.5 (25.1; 79.0) 43 112.2 (57.6; 218.6)  36  31.1 (15.1; 64.4) 48 86.8 (52.4; 143.7) 
Serotype 5       
 Month 0 48 21.2 (13.6; 33.1) 43 22.2 (16.3; 30.4)  36 32.2 (19.6; 53.0) 45  25.4 (18.0; 35.7) 
 Month 1 51 671.2 
(528.4; 852.5) 
45 477.1 
(376.7; 604.2) 
 38 733.7 
(528.5; 1018.7) 
49 470.4 
(377.6; 586.1) 
 Month 12 46 72.8 (50.0; 106.0) 34 38.4 (24.1; 61.0)  35 69.3 (45.4; 105.8) 48 40.1 (28.0; 57.4) 
Serotype 6A       
 Month 0 49 32.1 (15.3; 67.5) 44 525.5 (349.2; 790.9)  36 34.6 (15.3; 77.9) 47  119.9 (70.5; 203.8) 
 Month 1 51 4017.0 
(2708.5; 5957.8) 
45 8807.5 
(7174.8; 10811.6) 
 38 6389.4 
(4690.2; 8704.2) 
49 5991.7 
(3965.5; 9053.2) 
 Month 12 46 671.0 (414.2; 1087.1) 44 1097.4 (837.5; 1438.1)  38 710.6 (402.0; 1256.2) 49 966.7 (677.0; 1380.4) 
Serotype 6B       
 Month 0 50 408.6 (307.9; 542.3) 45 146.1 (81.4; 262.2)  36 358.5 (200.4; 641.3) 46 43.8 (21.5; 89.6) 
 Month 1 51 6289.5 
(4807.6; 8228.3) 
45 5577.0 
(4388.4; 7087.6) 
 38 6933.8 
(5165.6; 9307.2) 
49 4332.1 
(3203.6; 5858.1) 
 Month 12 48 657.3 (466.0; 927.0) 43 532.4 (348.2; 814.0)  38 389.2 (224.5; 674.6) 49 236.5 (144.3; 387.7) 
Serotype 6C       
 Month 0 49 24.3 (11.6; 50.8) 42 189.3 (92.8; 386.3)  36 23.4 (10.3; 53.1) 46 65.0 (31.0; 136.2) 
 Month 1 51 3207.6 
(2164.0; 4754.7) 
45 10499.0 
(8059.5; 13676.9) 
 38 1171.8 
(602.7; 2278.1) 
49 2680.1 
(1535.4; 4678.3) 
 Month 12 41 635.1 (310.3; 1300.1) 42 1031.1 (707.0; 1503.7)  36 189.4 (73.4; 488.9) 45 457.5 (239.0; 875.7) 
Serotype 7F       
 Month 0 51 585.4 (455.8; 751.9) 45 797.6 (624.4; 1018.8)  37 721.8 (533.7; 976.2) 49 614.3 (486.8; 775.3) 
 Month 1 51 3130.4 
(2605.1; 3761.6) 
45 6281.4 
(4528.6; 8712.5) 
 38 2792.3 
(2229.7; 3496.8) 
49 4801.4 
(3698.7; 6232.8) 
 Month 12 47 901.6 
(665.3; 1222.0) 
45 1470.7 
(1125.1; 1922.5) 
 38 857.1 
(554.2; 1325.7) 
49 1781.5 
(1405.7; 2257.8) 
Serotype 9V       
 Month 0 49 212.9 (136.4; 332.2) 41 157.6 (84.4; 294.5)  38 43.6 (22.4; 84.9) 46 44.3 (27.4; 71.8) 
 Month 1 51 2078.7 
(1664.4; 2596.1) 
45 4099.2 
(3032.7; 5540.8) 
 38 2305.9 
(1797.8; 2957.5) 
49 2815.0 
(2161.9; 3665.4) 
 Month 12 44 537.0 (368.8; 781.9) 44 732.9 (525.8; 1021.6)  38 526.4 (336.6; 823.1) 47 679.6 (419.2; 1101.9) 
Serotype 14       
 Month 0 51 531.8 (373.0; 758.1) 45 612.2 (397.9; 941.8)  36 405.8 (266.1; 618.6) 49 340.7 (226.5; 512.4) 
 Month 1 51 1780.5 
(1444.1; 2195.2) 
45 3376.4 
(2345.3; 4860.7) 
 38 1492.7 
(1158.4; 1923.4) 
49 2598.8 
(1932.1; 3495.4) 
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Serotype 
3+1 schedule (Czech Republic)  2+1 schedule (Slovakia) 
PHiD-CV group 
N = 53 
PCV13 group 
N = 45 
 PHiD-CV group 
N = 39 
PCV13 group 
N = 49 
 N GMT (95% CI) N GMT (95% CI)  N GMT (95% CI) N GMT (95% CI) 
 Month 12 48 576.3 (436.0; 761.6) 44 706.9 (453.2; 1102.6)  31 259.3 (138.0; 487.2) 47 361.4 (256.1; 510.1) 
Serotype 18C       
 Month 0 51 185.4 (110.0; 312.5) 44 104.6 (59.9; 182.5)  37 102.3 (60.2; 173.8) 48 33.6 (21.3; 52.8) 
 Month 1 51 2072.9 
(1680.9; 2556.4) 
45 2552.4 
(2002.4; 3253.5) 
 38 2122.1 
(1577.2; 2855.2) 
49 2270.4 
(1741.1; 2960.5) 
 Month 12 47 836.6 (595.6; 1175.3) 43 772.7 (536.6; 1112.9)  37 490.0 (276.4; 868.8) 49 714.6 (443.1; 1152.4) 
Serotype 19A       
 Month 0 50 13.4 (8.6; 20.7) 45 65.1 (39.6; 107.1)  38 13.8 (7.6; 25.0) 46 41.5 (28.0; 61.6) 
 Month 1 51 2778.6 
(2102.1; 3672.9) 
45 3004.9 
(2391.4; 3775.7) 
 38 1861.4 
(1361.6; 2544.5) 
49 2337.1 
(1865.1; 2928.7) 
 Month 12 47 266.9 (150.0; 475.2) 44 355.8 (219.9; 575.6)  36 204.8 (117.1; 358.2) 48 292.0 (183.0; 465.9) 
Serotype 19F        
 Month 0 51  192.7 (122.4; 303.5) 43 47.5 (28.8; 78.3)  38 157.5 (100.6; 246.7) 48 41.1 (27.3; 61.9) 
 Month 1 51 3868.0 
(3045.0; 4913.3) 
45 2769.6 
(2152.4; 3563.7) 
 38 2720.6 
(2054.4; 3603.0) 
49 2137.0 
(1655.0; 2759.4) 
 Month 12 48 586.7 (427.2; 805.8) 39 267.5 (143.2; 499.5)  38 210.2 (118.7; 372.4) 49 180.5 (115.7; 281.8) 
Serotype 23F        
 Month 0 49 68.1 (36.3; 127.8) 41 159.0 (79.5; 317.7)  38 83.7 (41.1; 170.6) 46 44.5 (23.0; 85.9) 
 Month 1 51 3470.9 
(2774.5; 4342.0) 
45 6561.6 
(4277.3; 10065.7) 
 38 3391.4 
 (2610.1; 4406.6) 
49 5238.2 
 (3985.7; 6884.4) 
 Month 12 47 709.3 (464.7; 1082.9) 44 1338.3 (888.9; 2015.0)  36 283.3 (130.1; 616.6) 48 788.1 (454.1; 1367.6) 
PCV13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal 
non-typeable Haemophilus influenzae protein D conjugate vaccine
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Supplementary Table 2. Percentage of subjects with OPA geometric mean titers ≥8 1 and 
12 months after the PCV13 booster dose 
  3+1 schedule (Czech Republic)  2+1 schedule (Slovakia) 
Serotype Timing 
PHiD-CV 
group 
N = 51 
PCV13 group 
N = 45 
 
PHiD-CV group 
N = 38 
PCV13 group 
N = 49 
Serotype 1 Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 22 (43.1%) 6 (13.3%)  19 (50.0%) 30 (61.2%) 
Serotype 3 Month 1 51 (100.0%) 45 (100.0%)  37 (97.4%) 49 (100.0%) 
 Month 12 24 (47.1%) 15 (33.3%)  20 (52.6%) 30 (61.2%) 
Serotype 4 Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 31 (60.8%) 32 (71.1%)  18 (47.4%) 40 (81.6%) 
Serotype 5 Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 43 (84.3%) 30 (66.7%)  33 (86.8%) 43 (87.8%) 
Serotype 6A Month 1 50 (98.0%) 45 (100.0%)  38 (100.0%) 48 (98.0%) 
 Month 12 44 (86.3%) 44 (97.8%)  35 (92.1%) 49 (100.0%) 
Serotype 6B Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 48 (94.1%) 41 (91.1%)  36 (94.7%) 46 (93.9%) 
Serotype 6C Month 1 50 (98.0%) 45 (100.0%)  35 (92.1%) 46 (93.9%) 
 Month 12 36 (70.6%) 42 (93.3%)  25 (65.8%) 39 (79.6%) 
Serotype 7F Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 47 (92.2%) 45 (100.0%)  37 (97.4%) 49 (100.0%) 
Serotype 9V Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 44 (86.3%) 44 (97.8%)  38 (100.0%) 47 (95.9%) 
Serotype 14 Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 48 (94.1%) 42 (93.3%)  29 (76.3%) 46 (93.9%) 
Serotype 18C Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 47 (92.2%) 43 (95.6%)  34 (89.5%) 47 (95.9%) 
Serotype 19A Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 43 (84.3%) 44 (97.8%)  33 (86.8%) 46 (93.9%) 
Serotype 19F Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 48 (94.1%) 36 (80.0%)  34 (89.5%) 47 (95.9%) 
Serotype 23F Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 47 (92.2%) 44 (97.8%)  36 (94.7%) 48 (98.0%) 
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Supplementary Table 3. Anti-pneumococcal antibody concentrations (95% CI) before and 
after the booster dose 
Serotype 
3+1 schedule (Czech Republic)  2+1 schedule (Slovakia) 
PHiD-CV group 
N = 53 
PCV13 group 
N = 45 
 PHiD-CV group 
N = 39 
PCV13 group 
N = 49 
 N GMC (95% CI) N GMC (95% CI)  N GMC (95% CI) N GMC (95% CI) 
Serotype 1       
 Month 0 51 0.22 (0.17; 0.27) 45 0.34 (0.28; 0.42)  38 0.27 (0.21; 0.34) 49 0.53 (0.45; 0.63) 
 Month 1 51 3.42 (2.72; 4.30) 45 2.54 (2.10; 3.09)  38 3.56 (2.75; 4.61) 49 4.31 (3.57; 5.20) 
 Month 12 48 0.40 (0.31; 0.51) 45 0.28 (0.23; 0.35)  38 0.41 (0.32; 0.54) 49 0.44 (0.37; 0.52) 
Serotype 3       
 Month 0 50 0.17 (0.12; 0.23) 45 0.24 (0.17; 0.33)  36 0.16 (0.12; 0.21) 49 0.35 (0.26; 0.47) 
 Month 1 48 1.12 (0.93; 1.35) 45 0.83 (0.64; 1.08)  34 1.10 (0.79; 1.54) 47 1.17 (0.90; 1.51) 
 Month 12 47 0.23 (0.17; 0.31) 44 0.20 (0.15; 0.28)  33 0.27 (0.18; 0.40) 47 0.25 (0.19; 0.33) 
Serotype 4       
 Month 0 51 0.31 (0.25; 0.39) 45 0.3 (0.24; 0.37)  38 0.37 (0.29; 0.49) 49 0.36 (0.30; 0.43) 
 Month 1 51 2.03 (1.72; 2.40) 45 2.77 (2.23; 3.45)  38 1.97 (1.53; 2.53) 49 2.58 (2.10; 3.17) 
 Month 12 48 0.21 (0.17; 0.25) 45 0.23 (0.18; 0.30)  38 0.17 (0.13; 0.21) 49 0.25 (0.20; 0.31) 
Serotype 5       
 Month 0 51 0.3 (0.25; 0.36) 45 0.31 (0.26; 0.38)  37 0.37 (0.30; 0.45) 49 0.34 (0.29; 0.40) 
 Month 1 51 1.24 (1.04; 1.48) 45 1.39 (1.15; 1.67)  38 1.28 (1.04; 1.59) 49 1.65 (1.34; 2.03) 
 Month 12 48 0.32 (0.25; 0.40) 45 0.29 (0.23; 0.37)  38 0.35 (0.29; 0.43) 49 0.33 (0.28; 0.40) 
Serotype 6A       
 Month 0 51 0.27 (0.20; 0.35) 45 0.54 (0.45; 0.65)  38 0.24 (0.17; 0.34) 49 0.68 (0.54; 0.86) 
 Month 1 51 6.29 (4.38; 9.04) 45 5.82 (4.83; 7.02)  37 4.60 (2.87; 7.37) 49 7.75 (6.27; 9.58) 
 Month 12 48 0.90 (0.64; 1.26) 45 0.63 (0.50; 0.80)  38 0.87 (0.64; 1.18) 49 1.15 (0.91; 1.45) 
Serotype 6B       
 Month 0 51 0.71 (0.58; 0.88) 45 0.37 (0.29; 0.47)  38 0.53 (0.40; 0.71) 49 0.24 (0.19; 0.31) 
 Month 1 51 13.07 (10.15; 16.83) 45 5.17 (4.39; 6.09)  38 10.25 (7.28; 14.42) 48 5.17 (4.02; 6.66) 
 Month 12 48 1.18 (0.87; 1.60) 45 0.71 (0.56; 0.90)  38 1.06 (0.80; 1.41) 49 0.85 (0.67; 1.10) 
Serotype 7F       
 Month 0 51 0.68 (0.54; 0.85) 45 0.77 (0.64; 0.93)  38 0.64 (0.51; 0.80) 49 0.72 (0.58; 0.88) 
 Month 1 51 3.34 (2.83; 3.93) 45 4.34 (3.71; 5.08)  38 2.78 (2.26; 3.42) 49 4.36 (3.55; 5.36) 
 Month 12 48 0.60 (0.50; 0.73) 45 0.69 (0.56; 0.85)  38 0.48 (0.40; 0.57) 49 0.71 (0.58; 0.87) 
Serotype 9V       
 Month 0 51 0.31 (0.24; 0.39) 45 0.26 (0.21; 0.31)  38 0.26 (0.21; 0.33) 49 0.29 (0.23; 0.38) 
 Month 1 51 2.08 (1.75; 2.48) 45 1.72 (1.34; 2.20)  38 2.11 (1.69; 2.63) 49 2.18 (1.76; 2.71) 
 Month 12 47 0.35 (0.27; 0.47) 45 0.25 (0.20; 0.33)  38 0.31 (0.25; 0.39) 49 0.37 (0.29; 0.48) 
Serotype 14       
 Month 0 51 1.84 (1.38; 2.45) 45 1.91 (1.46; 2.49)  38 1.83 (1.28; 2.61) 49 1.92 (1.39; 2.65) 
 Month 1 51 5.69 (4.64; 6.97) 45 7.60 (5.93; 9.75)  38 5.94 (4.75; 7.45) 49 9.16 (7.40; 11.34) 
 Month 12 48 0.87 (0.66; 1.13) 45 0.93 (0.67; 1.29)  38 0.94 (0.69; 1.28) 49 1.17 (0.91; 1.49) 
Serotype 18C       
 Month 0 50 0.46 (0.34; 0.62) 44 0.23 (0.18; 0.30)  38 0.43 (0.32; 0.58) 49 0.28 (0.22; 0.35) 
 Month 1 51 2.67 (2.13; 3.34) 45 2.00 (1.62; 2.47)  38 2.23 (1.73; 2.88) 49 2.22 (1.83; 2.70) 
 Month 12 48 0.28 (0.22; 0.35) 45 0.21 (0.16; 0.29)  38 0.30 (0.22; 0.39) 49 0.32 (0.26; 0.40) 
Serotype 19A       
 Month 0 51 0.33 (0.25; 0.42) 45 0.62 (0.45; 0.86)  38 0.38 (0.25; 0.57) 49 0.67 (0.55; 0.83) 
 Month 1 51 9.66 (6.70; 13.94) 45 9.72 (7.67; 12.32)  38 9.45 (6.80; 13.15) 49 8.22 (6.47; 10.45) 
 Month 12 48 1.30 (0.92; 1.82) 45 1.11 (0.78; 1.58)  38 1.11 (0.86; 1.44) 49 1.31 (1.00; 1.72) 
Serotype 19F        
 Month 0 51 1.83 (1.37; 2.44) 45 0.73 (0.59; 0.90)  38 2.03 (1.50; 2.74) 49 0.95 (0.80; 1.13) 
 Month 1 51 18.35 (13.70; 24.57) 45 7.65 (6.22; 9.40)  38 16.49 (11.94; 22.77) 49 9.36 (7.56; 11.60) 
 Month 12 48 1.90 (1.34; 2.70) 45 0.91 (0.68; 1.21)  38 1.72 (1.28; 2.30) 49 1.23 (0.98; 1.54) 
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Serotype 
3+1 schedule (Czech Republic)  2+1 schedule (Slovakia) 
PHiD-CV group 
N = 53 
PCV13 group 
N = 45 
 PHiD-CV group 
N = 39 
PCV13 group 
N = 49 
 N GMC (95% CI) N GMC (95% CI)  N GMC (95% CI) N GMC (95% CI) 
Serotype 23F        
 Month 0 51 0.41 (0.31; 0.55) 45 0.28 (0.22; 0.36)  38 0.34 (0.25; 0.46) 49 0.20 (0.15; 0.26) 
 Month 1 51 5.56 (4.18; 7.39) 45 4.35 (3.25; 5.82)  38 5.01 (3.56; 7.04) 49 3.62 (2.76; 4.76) 
 Month 12 48 0.47 (0.32; 0.70) 45 0.37 (0.27; 0.53)  38 0.37 (0.27; 0.53) 49 0.66 (0.41; 1.06) 
PCV13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-
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Supplementary Table 4. Percentage of subjects with IgG geometric mean concentrations 
≥0.35 µg/mL 1 and 12 months after the PCV13 booster dose 
  3+1 schedule (Czech Republic)  2+1 schedule (Slovakia) 
Serotype Timing 
PHiD-CV 
N = 51 
PCV13 
N = 45  
PHiD-CV 
N = 38 
PCV13 
N = 49 
Serotype 1 Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 28 (54.9%) 17 (37.8%)  25 (65.8%) 30 (61.2%) 
Serotype 3 Month 1 46 (90.2%) 39 (86.7%)  32 (84.2%) 45 (91.8%) 
 Month 12 17 (33.3%) 9 (20.0%)  14 (36.8%) 14 (28.6%) 
Serotype 4 Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 8 (15.7%) 11 (24.4%)  7 (18.4%) 15 (30.6%) 
Serotype 5 Month 1 51 (100.0%) 44 (97.8%)  38 (100.0%) 49 (100.0%) 
 Month 12 25 (49.0%) 17 (37.8%)  21 (55.3%) 26 (53.1%) 
Serotype 6A Month 1 49 (96.1%) 45 (100.0%)  35 (92.1%) 49 (100.0%) 
 Month 12 39 (76.5%) 38 (84.4%)  32 (84.2%) 47 (95.9%) 
Serotype 6B Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 47 (95.9%) 
 Month 12 42 (82.4%) 36 (80.0%)  34 (89.5%) 43 (87.8%) 
Serotype 7F Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 41 (80.4%) 38 (84.4%)  30 (78.9%) 44 (89.8%) 
Serotype 9V Month 1 51 (100.0%) 43 (95.6%)  38 (100.0%) 48 (98.0%) 
 Month 12 24 (47.1%) 14 (31.1%)  13 (34.2%) 25 (51.0%) 
Serotype 14 Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 42 (82.4%) 37 (82.2%)  33 (86.8%) 46 (93.9%) 
Serotype 18C Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 17 (33.3%) 10 (22.2%)  14 (36.8%) 21 (42.9%) 
Serotype 19A Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 42 (82.4%) 39 (86.7%)  36 (94.7%) 48 (98.0%) 
Serotype 19F Month 1 51 (100.0%) 45 (100.0%)  38 (100.0%) 49 (100.0%) 
 Month 12 46 (90.2%) 40 (88.9%)  37 (97.4%) 47 (95.9%) 
Serotype 23F Month 1 50 (98.0%) 44 (97.8%)  38 (100.0%) 49 (100.0%) 
 Month 12 32 (62.7%) 21 (46.7%)  18 (47.4%) 30 (61.2%) 
PCV13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-
typeable Haemophilus influenzae protein D conjugate vaccine 
